drugset / Trial / NCT04354831
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
Timeline
- Start
- 2020-05-11
- Primary completion
- 2021-02-10
- Completion
- 2021-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-SARS-CoV-2 convalescent plasma | Protein / enzyme biologic | 200 ml | Intravenous |
| Subject | anti-SARS-CoV-2 convalescent plasma | Protein / enzyme biologic | 400 ml | Intravenous |